Previous Article | Next Article ![]()
Journal of Bacteriology, May 2009, p. 2985-2992, Vol. 191, No. 9
0021-9193/09/$08.00+0 doi:10.1128/JB.01426-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
,
INSERM ESPRI 26, Université Montpellier 1 ERA 4204, Faculté de Médecine, Avenue Kennedy, CS 83021, 30908 Nîmes Cédex 2, France
Received 10 October 2008/ Accepted 6 February 2009
|
|
|---|
|
|
|---|
The key aspect of Brucella virulence is its ability to survive and proliferate within professional and nonprofessional phagocytes (7). Once phagocytosed, this bacteria subverts the vesicular traffic in the host cell to establish a niche in a compartment derived from the endoplasmic reticulum, where it multiplies (3, 34, 39, 40, 41). Several factors have been reported to be essential for the virulence of this bacterium (16, 17, 18, 19, 21, 22, 29, 31). Strikingly, we (36) and others (44) have demonstrated the presence in Brucella of a type IV secretion system (T4SS) that is encoded by the virB operon and whose integrity is required for virulence (8, 14, 19). Several other species of gram-negative bacteria have been found to rely on the presence of a T4SS for full virulence (10, 13). Both extracellular (Helicobacter) and intracellular (Legionella, Bartonella) pathogens use their T4SSs to inject effector proteins directly into the target cell, where they affect the biology of the cell. Bordetella pertussis uses its T4SS to secrete the pertussis toxin into the extracellular medium, where it is taken up by cells. The T4SS of Agrobacterium tumefaciens translocates both effector proteins and a nucleoprotein complex into target plant cells through a mechanism reminiscent of bacterial conjugation through T4SS.
The A. tumefaciens VirB T4SS, which is considered the T4SS paradigm, is composed of 11 different proteins named VirB1 to VirB11 plus VirD4. These proteins can be functionally subdivided in three different groups. The proteins VirB4, VirB11, and VirD4 are inner membrane ATPases with a large cytoplasmic domain and are believed to provide the energy required for T4SS assembly and for the translocation of effectors. VirB2 and VirB5 form an extracellular bacterial appendage believed to anchor the bacteria to the host cell (4, 25). Finally, VirB3 and VirB6 to VirB10 are believed to form a channel-like structure spanning both the inner and outer membranes of the bacteria.
Among these structural proteins, VirB8 has been shown to play a key role in the assembly of the T4SS. Recent studies with A. tumefaciens demonstrated that VirB8 acts as a nucleation center required to recruit VirB9 and VirB10 into clusters in the outer membrane (15, 30) and to localize VirB proteins at the cell pole (26). VirB8 is a protein spanning the bacterial inner membrane, with the first 67 amino acids forming a short cytoplasmic tail, followed by a single hydrophobic transmembrane (TM) domain. The carboxy-terminal moiety of the protein, of 172 amino acids, is believed to be entirely periplasmic. Recently, the three-dimensional structures of the periplasmic domains of VirB8 from Brucella suis (46) and A. tumefaciens (5) have been determined. Using these structural data, site-directed mutagenesis has been performed on the periplasmic part of B. suis VirB8, showing that changes in amino acids that inhibit the dimerization of VirB8 or its interactions with VirB4 or VirB10 also affect T4SS assembly and B. suis virulence (37). Among all of the homologs of B. suis VirB8, the closest are the proteins TraJ, encoded in the tra operons of broad-host-range plasmids pSB102 and pIPO2 (43, 45). The TraJ protein from pSB102 shares more than 50% identity with B. suis VirB8 at the amino acid level, and this percentage increases to more than 60% when only the periplasmic domain is considered. In a previous study, we have taken advantage of this close similarity between VirB8 and TraJ to examine the possibility of a functional heterologous complementation of VirB8 by TraJ in BS1008, a B. suis mutant carrying an in-frame deletion of the virB8 gene (38). From our results, it appeared that the protein TraJ was unable to complement BS1008. As the major similarities between VirB8 and TraJ were found in their respective periplasmic domains, we constructed chimeric genes encoding proteins in which the major part of the periplasmic domain of one protein (amino acids 77 to 241 of TraJ and amino acids 76 to 239 of VirB8) was replaced with the corresponding part of the other protein (these proteins are described in Fig. 1) and studied the ability of these chimeric proteins to restore the virulence of BS1008. The TraJB8 chimera, where the periplasmic part of VirB8 replaces the corresponding part of TraJ, was also unable to complement BS1008. In contrast, B8TraJ, the reverse chimera in which the periplasmic part of TraJ replaces the corresponding part of VirB8, partially restored the virulence of BS1008. These results show that, when fused to the cytoplasmic and TM parts of VirB8, the periplasmic part of TraJ can functionally replace the corresponding part of VirB8 in T4SS assembly. In contrast, the cytoplasmic and TM parts of TraJ cannot replace the corresponding part of VirB8, whether fused to the periplasmic part of TraJ or VirB8. To further elucidate these points, we undertook a more detailed study of the interactions of these proteins by bacterial two-hybrid (BACTH) analysis. Here we show that the proteins VirB8, B8TraJ, TraJB8, and TraJ display strikingly different abilities to interact with themselves, as well as with VirB8 itself. Further, the TM domain of these proteins plays a crucial role in determining the strength of these interactions. Finally we show that, when overexpressed in a wild-type B. suis strain, these various proteins are able to modulate its virulence, even leading to complete loss of virulence. These data give interesting clues concerning the mechanisms of type IV secretion.
![]() View larger version (50K): [in a new window] |
FIG. 1. Schematic representation of the proteins used in this study. Light and dark gray parts represent protein domains from VirB8 and TraJ, respectively. All proteins were synthesized as fusion proteins with the T18 or T25 subunit of the B. pertussis adenylate cyclase domain fused to the amino-terminal end of the VirB8- and/or TraJ-containing part. In the case of the periplasmic domains of VirB8 (VirB8p) and TraJ (TraJp), synthesis of these proteins as fusions with the subunits of B. pertussis adenylate cyclase likely targets them to the bacterial cytoplasm, as suggested by fractionation studies. The rightmost column indicates whether the corresponding proteins have (+) or have not (–) been detected in Western blotting experiments.
|
|
|
|---|
or XL1-Blue strain by using standard cloning protocols. Transformants were selected on 2YT agar containing the appropriate antibiotic (ampicillin, 100 µg/ml; kanamycin, 25 µg/ml; chloramphenicol, 30 µg/ml), and cultures were grown in 2YT medium containing the same antibiotic. BACTH experiments were performed with the adenylate cyclase-deficient strain E. coli BTH101 as described previously (27). All experiments included a positive control (plasmids encoding fusion proteins with a leucine zipper from Saccharomyces cerevisiae GCN4) and a negative control (empty plasmids). Wild-type strain B. suis 1330 was transformed by electroporation as previously described (38). All of the resulting Brucella strains were used to infect J774 murine macrophage-like cells in a standard gentamicin protection assay as described previously (38). Plasmids. The PCR primers used in this study are described in Table 1, and the plasmids used are described in Table 2. Plasmid pIN73 was derived from pUT18C (27) by replacing a PstI-EcoRI fragment containing the polylinker with the corresponding fragment of pKT25. Plasmid pIN94 was obtained from pKT25 by filling in the unique XbaI site of the polylinker with the Klenow fragment of E. coli DNA polymerase. All of the other plasmids used in the BACTH studies were derived from pIN73 and pIN94 by inserting DNA fragments obtained by PCR between the unique BamHI and EcoRI sites. The construction of some derivatives of pBBR1-MCS used in infection studies has already been described (38). Other plasmids were designed specifically for this study from plasmids used for BACTH analysis.
|
View this table: [in a new window] |
TABLE 1. Primers used in this study
|
|
View this table: [in a new window] |
TABLE 2. Plasmids used in this study
|
Western blotting. To study the stability of the proteins used for BACTH analysis, we transformed BTH101 simultaneously with the pIN94-derived plasmid expressing the protein of interest fused to the T25 subunit of B. pertussis adenylate cyclase and the pIN-derived plasmid expressing the same protein fused to the T18 subunit, followed by a FLAG epitope. One colony of each transformation was cultured overnight at 37°C in 1 ml LB medium containing ampicillin, kanamycin, and IPTG. Bacteria were pelleted (4,000 x g, 5 min, 4°C). In some experiments, a fraction corresponding to the bacterial periplasm was first isolated from the bacterial pellet by osmotic shock in 5 mM MgSO4 (35). Otherwise, the pellets were resuspended in 100 µl of 50 mM Tris-HCl buffer (pH 8) containing 5 mM EDTA, a cocktail of protease inhibitors (leupeptin and antipain both at a 1-µg/ml final concentration and phenylmethylsulfonyl fluoride at a 100-µg/ml final concentration), and lysozyme at a final concentration of 0.25 mg/ml until the cells were lysed. When the suspension became viscous, 10 µl of a solution containing 0.02 mg/ml DNase I, 1.5 M NaCl, 0.1 M CaCl2, and 0.1 M MgCl2 was added. When the suspension was no longer viscous, it was centrifuged (25,000 x g, 30 min, 4°C). Aliquots of the supernatant and the resuspended pellet were diluted with an equal volume of gel loading buffer, boiled, and loaded onto a 12% polyacrylamide gel. The resolved proteins were transferred to a polyvinylidene difluoride membrane (Immobilon PVDF; Millipore). The membranes were then assayed for the presence of proteins containing the FLAG epitope by using a monoclonal antibody directed against this epitope and coupled to horseradish peroxidase (HRP; Sigma). HRP activity was detected with a chemiluminescent substrate (Immobilon Western HRP substrate; Millipore).
Growth kinetics of Brucella strains. Wild-type B. suis strain 1330 and the strains used in the macrophage infection study were grown overnight at 37°C in 2YT medium. The resulting cultures were diluted in 2YT to obtain an optical density at 600 nm (OD600) of 0.1. The diluted cultures were further grown at 37°C, and the OD600s were measured every 2 h for 8 h. The doubling time (T) of each strain was calculated from the slope (m) of the straight line obtained by plotting the ln of the OD600 as a function of the incubation time by using the formula T = ln 2/m.
|
|
|---|
![]() View larger version (32K): [in a new window] |
FIG. 2. Expression and stability of various FLAG-tagged proteins expressed in BTH101 bacteria. Bacterial extracts were obtained as described in Materials and Methods. After sodium dodecyl sulfate-polyacrylamide gel electrophoresis of crude bacterial extracts, Western blotting revealed FLAG-tagged proteins with a specific monoclonal antibody against the FLAG epitope. The fusion proteins synthesized by the bacteria in panel A are B8p (lane 1), TraJp (lane 2), VirB8 (lane 3), TraJ (lane 4), B8TraJ (lane 5), and TraJB8 (lane 6), and those in panel B are TraJCyTM (lane 1), B8CyTM (lane 2), JCyB8TM (lane 3), B8CyJTM (lane 4), B8Cy (lane 5), TraJCy (lane 6), B8TM (lane 7), and TraJTM (lane 8).
|
![]() View larger version (38K): [in a new window] |
FIG. 3. Homodimeric and heterodimeric interactions between the periplasmic domains of VirB8 and TraJ. The first protein was synthesized from high-copy-number plasmid pIN73, and the second was synthesized from low-copy-number plasmid pIN94. Following overnight culture at 30°C (left panel) or 37°C (right panel), β-galactosidase activities were measured as described in Materials and Methods. Results are the mean ± the standard error of the mean of at least three different cultures.
|
![]() View larger version (24K): [in a new window] |
FIG. 4. Homodimeric interactions between full-length proteins (left panel) or cytoplasmic and TM domains (right panel). Following overnight culture at 37°C, β-galactosidase activities were measured as described in Materials and Methods. Results are the mean ± the standard error of the mean of at least three different cultures.
|
Heterodimeric interactions with VirB8. Sequence comparisons suggest that the periplasmic domain of TraJ could functionally replace the corresponding domain of VirB8 (see Discussion). We first used BACTH analysis to investigate whether the periplasmic domains of VirB8 and TraJ could interact to form heterodimers (Fig. 3). At 37°C, heterodimers were formed with β-galactosidase activity higher than that of the homodimers, again suggesting a stronger interaction. We then examined the formation of heterodimers between full-length VirB8 and full-length TraJ or the chimeras. Here again, all of the combinations could form heterodimers. As with the homodimers, the presence of the cytoplasmic and TM regions of TraJ (TraJ and TraJB8) resulted in at least 10-fold higher activities, suggesting much stronger interactions than with the corresponding regions of VirB8 (VirB8 and B8TraJ) (Fig. 5).
![]() View larger version (38K): [in a new window] |
FIG. 5. Heterodimeric interactions between full-length wild-type proteins or chimeras (pIN73) and full-length VirB8 (pIN94). Following overnight culture at 37°C, β-galactosidase activities were measured as described in Materials and Methods. Results are the mean ± the standard error of the mean of at least three different cultures.
|
![]() View larger version (21K): [in a new window] |
FIG. 6. Comparison of the virulence of wild-type B. suis 1330 (S1) and S1 containing the empty pIN34 plasmid with S1 overexpressing different VirB8 proteins. J774 murine macrophage-like cells were infected in a standard gentamicin protection assay as described previously (37). Intracellular survival and multiplication of the bacteria were followed at different times after the beginning of the infection. The results shown are representative of at least three independent experiments.
|
|
View this table: [in a new window] |
TABLE 3. Growth rates of bacterial strains used in macrophages infection studies
|
|
|
|---|
Despite a high degree of sequence similarity, the full-length TraJ protein could not restore the virulence of a B. suis virB8 mutant (38); however, a B8TraJ chimera could do so, at least partially. The results of our previous study with TraJ and the chimeras could be interpreted as meaning that the cytoplasmic and/or TM domains of TraJ do not allow proper interactions between the two subunits of the homodimer TraJ-TraJ or TraJB8-TraJB8 to take place, thus leading to a nonfunctional T4SS. BACTH analysis showed that VirB8, TraJ, TraJB8, and B8TraJ can form homodimers and that the interactions of either TraJ or TraJB8 are, in fact, much stronger than those of VirB8 or B8TraJ (Fig. 4). Western blotting showed that, at least for the periplasmic domains and the full-length proteins and chimeras, the differences observed in β-galactosidase activity are not due to a lack of stability or a mislocalization of these proteins.
Sequence comparisons suggest why the periplasmic domain of TraJ could functionally replace the corresponding domain of VirB8 in B. suis. Almost all of the amino acids in the periplasmic domain which have been shown to play an important role in VirB8 function are strictly conserved in TraJ (37, 38, 46). Amino acids Met102, Tyr105, and Glu214, implicated in VirB8 dimerization, have as their counterparts Met103, Tyr106, and Glu215 in TraJ, suggesting that the periplasmic domain of TraJ should also form heterodimers with the periplasmic domain of VirB8. BACTH analysis confirmed that VirB8p and TraJp can form heterodimers with interactions apparently stronger than in homodimers. Amino acids Thr201 and Arg230 which are, respectively, involved in the interactions between the periplasmic domain of VirB8 and the periplasmic domain of VirB10 and with VirB4, correspond to amino acids Thr202 and Arg231 in TraJ. This suggests that the periplasmic domain of TraJ should also be able to interact with these proteins in the VirB T4SS, allowing correct assembly of the T4SS. The amino acids located close to the deep groove found in the structure of the periplasmic domain of VirB8, such as Trp119, Tyr126, Leu151, Asp152, and Lys182, are all conserved in TraJ. The only exception is the replacement of Gln144 of VirB8 with Leu145 in TraJ. Finally, one notable difference between the periplasmic domains of VirB8 and TraJ is the replacement of Ile112, located at the interface between the two subunits of a homodimer, with Arg113 of TraJ. It is worth noting that in the periplasmic domain of A. tumefaciens VirB8, the Arg107 residue is found at the same position (5).
The proteins JCyTM and B8CyJTM, containing the TM domain of TraJ preceded by the cytoplasmic domain of either TraJ or VirB8, were both expressed at high levels and interact strongly, forming homodimers (Fig. 4). In contrast, certain proteins containing the TM domain of VirB8 (JCyB8TM and B8CyTM) appeared unstable, explaining the lack of interaction in the BACTH assay. A closer examination of the amino acid sequence of the TM domains of VirB8 and TraJ revealed striking features. Clustal alignment of the two sequences shows that Tyr50 in TraJ corresponds to a gap in the sequence of VirB8 and that Trp60 in TraJ corresponds to Gly59 in VirB8 (see Fig. 3 in reference 38). Both Tyr and Trp residues are much more hydrophobic and bulky than Gly or Ala, the residues located in VirB8 (positions 48 to 50 and 59), suggesting that the presence of these bulky amino acids in the TM domain could be, at least in part, responsible for the stronger interactions.
The full-length proteins containing the TM domain of TraJ formed very strong interactions with VirB8, suggesting that an excess of one protein containing this TM domain in a wild-type B. suis strain could adversely affect its virulence. Overexpression of TraJ or TraJB8 in a wild-type Brucella strain was found to strongly attenuate its virulence. We believe that this is due to the formation of strongly interacting heterodimers. Overexpression of VirB8 or B8TraJ also had a small attenuating effect, suggesting that stoichiometry is also important. Our results raise several questions concerning the assembly and function of the T4SS. The inability of a protein containing the TM domain of TraJ to complement a VirB8 mutant, as well as the dominant negative effects on virulence, may be due to incorrect assembly of the T4SS. We have no way to test T4SS assembly in Brucella; however, we could test the effects of the proteins carrying the TraJ TM domain in the recently described heterologous system in which the whole B. suis T4SS expressed in A. tumefaciens increases its ability to serve as a recipient in T4SS-mediated plasmid conjugation (9). This is thought to be a measure of T4SS assembly (9, 32).
The T4SS can also be viewed as a dynamic structure. Using the TrIP assay, the Christie group has been able to follow the pathway that the T-DNA complex takes across the VirB channel (11). A combination of immunoprecipitation of selected VirB/D4 proteins and PCR amplification of the Ti plasmid was used to identify contacts between the T-DNA and components of the virB/D4 conjugation system. The T-DNA could be found first bound to the protein VirD4 and then successively to the proteins VirB11, VirB6, VirB8, VirB9, and VirB2. In addition, although not directly binding the T-DNA, proteins VirB3, VirB4, VirB5, VirB7, and VirB10 were absolutely required for the T-DNA to pass through the different steps of this pathway. If we assume a similar role for VirB8 in Agrobacterium and Brucella, we can predict that this protein will interact with effectors during translocation. VirB7, -9, and -10 have recently been shown to form a double-walled channel spanning both membranes of the bacterial envelope (20). One can imagine that the T4SS must be "closed" to stop leakage and then "open" transiently to allow substrate passage; we can speculate that VirB8 may play the role of "gatekeeper," controlling the passage of the substrate through the channel. Further support for the dynamic nature of T4SS comes from data showing that the VirB10 protein undergoes ATP-dependent conformational changes which result in the formation of transient "bridges" linking inner and outer membrane-associated subassemblies of the T4SS (12). In addition to playing an essential role in the translocation of effectors, VirB8 is involved in numerous protein-protein interactions, particularly with other VirB proteins (15, 17, 22, 24, 26, 30, 46, 47, 49). However, it has been suggested (6) that, given its relatively small size, VirB8 is unlikely to engage simultaneously in such a large number of interactions. This implies that these interactions might occur transiently at defined time points during the translocation process, with possible conformational changes in VirB8 allowing these different interactions to take place. Dimerization of VirB8 can therefore be viewed as a transient state during the translocation process, resulting in a dynamic equilibrium between monomers and dimers of this protein in the T4SS.
T4SSs have been very elusive structures in most animal pathogens and to date have only been visualized on Helicobacter pylori (2, 42). Taking the notion of a dynamic structure to an extreme, could this be because they are, in fact, very transient, only fully assembled when needed and then rapidly disassembled once the effector molecules have been translocated?
Published ahead of print on 27 February 2009. ![]()
Supplemental material for this article may be found at http://jb.asm.org/. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»